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Introduction: With the shortage of donor organs for islet transplantation, insulin-producing cells have been
generated from different types of stem cell. Human fetal pancreatic stem cells have a better self-renewal capacity
than adult stem cells and can readily differentiate into pancreatic endocrine cells, making them a potential source
for islets in diabetes treatment. In the present study, the functions of pancreatic islets derived from human fetal
pancreatic progenitor cells were evaluated in vitro and in vivo.
Methods: Human pancreatic progenitor cells isolated from the fetal pancreas were expanded and differentiated
into islet endocrine cells in culture. Markers for endocrine and exocrine functions as well as those for alpha and
beta cells were analyzed by immunofluorescent staining and enzyme-linked immunosorbent assay (ELISA). To
evaluate the functions of these islets in vivo, the islet-like structures were transplanted into renal capsules of diabetic
nude mice. Immunohistochemical staining for human C-peptide and human mitochondrion antigen was applied to
confirm the human origin and the survival of grafted islets.
Results: Human fetal pancreatic progenitor cells were able to expand in medium containing basic fibroblast growth
factor (bFGF) and leukemia inhibitor factor (LIF), and to differentiate into pancreatic endocrine cells with high efficiency
upon the actions of glucagon-like peptide-1 and activin-A. The differentiated cells expressed insulin, glucagon, glucose
transporter-1 (GLUT1), GLUT2 and voltage-dependent calcium channel (VDCC), and were able to aggregate into islet-like
structures containing alpha and beta cells upon suspension. These structures expressed and released a higher level of
insulin than adhesion cultured cells, and helped to maintain normoglycemia in diabetic nude mice after transplantation.
Conclusions: Human fetal pancreatic progenitor cells have good capacity for generating insulin producing cells and
provide a promising potential source for diabetes treatment.Introduction
The success of islet transplantation over the last decade
suggests that diabetes can be cured by a replenishment
of deficient beta cells [1,2]. However, according to the
transplantation protocol of Edmonton, the transplanted
islets into each patient should be isolated from two to
three pancreatic donors, exceeding ten thousand islet
equivalent (IEQ)/kg [3]. As a result, a widespread use of
islet transplantation is severely limited by the shortage of
donor organs. Stem cells have the capacity of self-renewal* Correspondence: Lou.j@mail.com
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reproduction in any medium, provided the orand the potential of differentiating into various cell types,
making them an ideal candidate to address this issue.
Although the possibility of generating insulin-producing
cells routinely from both human embryo stem cells
(ESC) and human induced pluripotent stem (iPS) cells
is quite encouraging, significant challenges still remain [4].
Lumelsky [5] and Assady [6] found that islet-like cells
could be generated in vitro by differentiation of ESC under
conditions resembling those of physiological development
for pancreatic beta cell development. However, insulin
secretion by these cells was low and lacked a full response
to glucose. Clinically, applying ESC-derived cells in treatment
presents more challenges including the risk of cancer forma-
tion, functional deficiency of such cells and controversial
ethical issues. Deriving insulin-releasing cells from iPS cellsLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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were able to efficiently induce iPS cells into insulin-producing
cells, only about 10% of the cells became productive [7].
Human adult stem cells derived from various tissues
were also explored for generating insulin-producing cells.
Kadam et al. expanded mesenchymal stromal cells from
human umbilical cord and placenta, and differentiated
them into functional islets in vitro [8]. Chandra et al. [9]
reported that islet-like cell aggregates derived from stem
cells in human adipose tissue ameliorated experimental
diabetes in mice. However, the extent of endocrine cell
formation and insulin secretory function were insufficient
to become clinically applicable [10].
It has been demonstrated that stem cells are available in
pancreatic ducts and islets, with the capability of differenti-
ating into pancreatic exocrine and endocrine cells [11,12],
and the number of pancreatic stem cells increased upon
partial pancreatectomy or destructive immune response
[13]. Thus, it is possible that pancreatic stem cells might be
promoted to differentiate into functional islet endocrine
cells under in vitro culture conditions [14].
It is known that pancreatic stem cells differentiating
toward endocrine cells express pancreatic duodenal homeo-
box-1(PDX-1) and neurogenin 3. Bonner-Weir et al. [15]
showed that human pancreatic duct cells could be ex-
panded and differentiated into glucose responsive islet
tissue in vitro given ITS (insulin, transferrin, selenium),
nicotinamide and keratinocyte growth factor. Ramiya et al.
[14] isolated murine pancreatic ductal epithelial cells into
culture, and induced them into functional islets containing
alpha, beta and delta cells. These resulting islets showed
temporal changes in mRNA transcripts for islet cell-
associated differentiation markers, responded to glucose
challenge in vitro and reversed insulin-dependent diabetes
after being implanted into non-obese diabetic mice.
While pancreatic stem cells isolated from adult pancreas
have low proliferative capability [16], fetal pancreatic cells
have shown stronger proliferative potential in vitro, even
those obtained during the second or third trimester [17].
Moreover, human fetal pancreatic progenitor cells also have
the capability of differentiating into insulin-producing cells
in vitro [18-20]. In the present study, we demonstrate that
pancreatic stem cells isolated from human fetal pancreas
have the capacity not only to expand and differentiate
extensively into islet endocrine cell in vitro but also to
correct high blood glucose efficiently in diabetic animals.
Methods
Isolation, purification and identification of human
pancreatic progenitor cells
The present study was approved by the Clinical Research
Ethics Committee of China-Japan Friendship Hospital and
conducted according to the principles of the Declaration
of Helsinki. Five human fetal pancreases at the 10th to12th gestational week were obtained from abortion pa-
tients in China-Japan Friendship Hospital, in which
one was a spontaneous abortion due to low progesterone
level and the other four were intended abortions according
to the mothers’ choice. All the tissues were obtained follow-
ing medical ethics and all with patient informed consent.
Pancreas tissues at the 10th to 12th gestational week
were confirmed to be abundant with islet-like structures
which were CD133 positive but insulin negative by immu-
nohistochemistry staining. The pancreatic tissues were
digested with XI collagenase (Sigma, Shanghai, China),
and the islet-like structures extracted were suspended in
(D)MEM/F12 (Sigma) in a 35-mm cell culture dish. After
slowly hand-shaking the dish, the islet-like structures would
move to the middle of the dish and were picked up using a
pipette under a stereomicroscope (Nikon, Beijing, China).
The islet-like structures were resuspended and cultured
in a 37°C, 5% CO2 incubator in (D)MEM/F12 medium
containing 5% fetal calf serum for stem cell, 40 μg/L
leukemia inhibitor factor (LIF), 10 μg/L basic fibroblast
growth factor (bFGF), 10 μg/L epidermal growth factor
(EGF), 105 U/L penicillin and 100 mg/L streptomycin [5]
Adherent cells that grew from the islet-like structures after
24 hours were trypsinized for passage with 0.1% trypsin/
0.1% ethylenediaminetetraacetic acid (EDTA) solution at
confluence. The propagated cells were saved for further
study. The control human islets were isolated from a
section of pancreas after pancreatectomy from a patient
with a pancreatic tumor, as previously described [21].
RT-PCR was employed to detect the following markers
for proliferated stem cells: Oct4, ATP-binding cassette
superfamily G member 2 (ABCG2), stem cell factor (SCF),
CD133, carbonic anhydrase II (CAII), cytokeratin 19 (CK19),
PDX-1 and neurogenin 3. The expression of PDX-1 and
Neurogenin 3 (Ngn3) was also confirmed by immuno-
fluorescence staining using goat anti-human PDX-1
antibody (Abcam, Cambridge, MA, USA) and rabbit
anti-human Ngn3 antibody (Abcam). After two, five and
ten passages, cells were collected to measure the expres-
sion levels of smooth muscle actin (SMA), vimentin, stem
cell markers (Oct4, PDX-1 and CA II) and mature cell
markers (insulin and glucagon) by real-time PCR.
Induced differentiation of human pancreatic
progenitor cells
Human fetal pancreatic progenitor cells were induced in
M199 medium containing 15% fetal bovine serum (FBS),
10 mmol/L nicotinamide, 30 ng/ml all-trans retinoic acid
and 42 ng/ml glucagon-like peptide-1 (gift of Shanghai
Huayi Bio-Lab Co. Ltd) for four weeks. The medium was
replaced every three days and 50 ng/ml activin A was
added to the medium in the last week. The flowchart of the
differentiation protocol is as follow (Nico, nicotinamide;
RA, all-trans retinoic acid):
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After four weeks of directed differentiation, the cells were
harvested and aggregated in suspension culture under
special conditions. In brief, the cells were resuspended in
M199 containing 20% FBS, 1.5 mmol/L Ca2+, 1 mmol/L
ATP, 2 mmol/L glutamine, 2 μg/ml laminin, 5 μg/ml Type
IV collagen and 3 μg/ml fibronectin. The mixture was
transferred to a nontreated flask or siliconized centrifugal
tubes and placed into a 37°C, 5% CO2 incubator. Gentle
agitation was applied every eight hours. After a 24-hour
incubation, small cell aggregations formed and were
harvested by centrifugation at 1,200 rpm for eight minutes.
The morphology of islet-like structures was examined
under a stereomicroscope.
Immunofluorescent staining
The islets differentiated from progenitor cells were selected
manually, embedded in optimal cutting temperature (OCT)
compound and prepared into frozen sections. The expres-
sions of insulin and glucagon were examined and compared
with adult islets as control. The frozen sections were then
fixed for one minute with alcohol (95%), washed three
times with PBS solution and blocked for 30 minutes at
room temperature with 0.1% BSA/PBS. Then anti-insulin
and anti-glucagon antibodies (Sigma) were incubated over-
night, respectively, with the cells at 4°C. After the sections
were rinsed three times with PBS solution, Alex488-labeled
secondary antibody (Invitrogen Inc, Grand Island, NK,
USA) was added and incubated with the cells for another
30 minutes. A fluorescent microscope was used to observe
the results.
Transmission electron microscopy
Adult islets and differentiated cells were collected by
centrifugation and washed with PBS, then fixed with 2.5%
glutaraldehyde for 30 minutes at room temperature. Cells
were washed, post-fixed, dehydrated and embedded with
Epon 812 (Electron Microscopy Sciences, Beijing, China).
The sections were examined under a JEM-1010 electron
microscope (JEOL Inc, Tokyo, Japan). Five fields were ex-
amined for each sample.
Real-time PCR
Total RNA was extracted from cells 0, 3 and 4 weeks
post differentiation and from islet-like structures 4 weeks
post differentiation using a RNEasy Mini kit (QiagenInc, Hilden, Germany). A total of 1 μg RNA was used
for reverse transcription using omniscript reverse tran-
scriptase (Qiagen). Real-time PCR was performed on
an Applied Biosystems instrument (ABI 7500 system),
using SYBR Green PCR Master Mix (ABI Inc, Foster city,
CA, USA) and 40 reaction cycles. Markers for pancre-
atic stem cells, endocrine, exocrine and mesenchymal
cells were measured at different time points of expansion
and differentiation At the end of each reaction, melting-
curve analysis was performed to confirm the absence of
primer dimers. The expression levels of genes of interest
were normalized to the expression level of GAPDH. Data
were analyzed using the 2- ΔCt method. The pancreatic
stem cell markers (CAII, PDX-1, Neurogenin 3; endo-
crine markers: insulin, glucagon, GLUT1, GLUT2 and
VDCC), as well as exocrine markers (HES-1 and amylase)
were evaluated during differentiation. The mesenchymal
markers SMA and vimentin were evaluated during pan-
creatic stem cell expansion. The gene-specific primer se-
quences are shown in additional file (see Additional file 1).Insulin release assay by ELISA
After pre-incubation with Krebs-Ringer buffer at 37°C
for 90 minutes, the progenitor cell-derived islets (100
IEQs/ml) were incubated with Krebs-Ringer buffer contain-
ing 2.5 mM glucose or 25 mM glucose at 37°C for different
durations. Conditioned medium was then collected, cen-
trifuged and assayed for insulin content by an ELISA kit
(Linco Inc, St Charles, MO, USA).Animal experiments
Diabetic animal models
The animal study was approved by the Animal Ethics
Committee of China-Japan Friendship Hospital. Twelve
male nude BALB/c mice, four- to six-weeks-old, were
purchased from Vital River Laboratories (quality certificate:
SCXK (Beijing) 20060009)–. All animals were housed in
the specific pathogen free (SPF) facility of the Institute of
Clinical Research at our hospital. The diabetic model was
induced in the mice by an intraperitoneal injection of
streptozocin (200 mg/kg body weight; Sigma, St. Louis,
MO, USA) freshly dissolved in citrate buffer (pH 4.5).
Blood samples were taken from the tail vein of the animals
under non-fasting conditions (8:00 A.M.; standard la-
boratory diet ad libitum overnight) and examined for
A B
DC
Figure 1 Isolation of progenitor cells from human fetal
pancreatic tissue. (A and B) The histological feature of human fetal
pancreas at the 11th gestational week was immunochemistry
stained for CD133 (A) and insulin (B). (C) Islet-like structures isolated
from human fetal pancreas. (D) Progenitor cells grew out from the
islet-like structures after 24 hours of culture. The progenitor cells
exhibited epithelial-like morphology.
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Easy™, Johnson & Johnson, Shanghai, China). Only animals
exhibiting blood glucose concentrations >20 mM in three
consecutive measurements were employed in the study.
They were assigned randomly into a control group and a
progenitor cell-derived islet group (n = 6 each).
Transplantation of differentiated islet-like structures
To evaluate the function of progenitor cell-derived islet-like
structures, they were transplanted under the capsule of the
left kidney of diabetic mice. Blood glucose was measured
regularly after transplantation. When euglycemia was main-
tained for one week, the left kidney with transplants was
excised surgically and examined by immunohistochemistry
for human C-peptide and human mitochondrion antigen
as described below. Blood glucose was monitored regularly
after surgery.
Histological examination
In order to verify further the functionality of human
pancreatic progenitor cell-derived beta cells in vivo, the
animals were sacrificed at the end of experiment. Left
murine kidneys were embedded in paraffin. Then murine
kidneys were immunostained for human C-peptide (mouse
anti-human C-peptide, Chemicon, Temecula, CA,
USA) and human mitochondrion antigen (mouse anti-
human mitochondrion, Millipore, Billerica, MA, USA) to
confirm the survival and functionality of transplanted
human islet-like structures.
Statistical analysis
The analysis was conducted with SPSS11.0 software and
the data were expressed as mean ± SD. The t test was
uesed for comparison between two groups and one way
analysis of variance (ANOVA) for comparisons among
multiple groups. P <0.05 and P <0.01 denoted statistical
significance.
Results
Isolation, purification and identification of pancreatic
progenitor cells
Between 10 to 12 weeks post conception, the pancreas
contained many tubular structures within a loose mesen-
chymal stroma. These tubular structures consisted of epi-
thelial cells which were CD133 positive (Figure 1A) but
insulin negative (Figure 1B), indicating progenitor cells.
After digestion with XI collagenase, the mesenchymal tissue
was destroyed and islet-like structures were harvested
(Figure 1C). The progenitor-containing clusters adhered
after 24 hours and the progenitor cells began expanding
(Figure 1D). These cells exhibited monolayer growth and
proliferated quickly in medium containing bFGF, EGF and
LIF, and confluent cells were epithelial-like (Figure 1D).The results of RT-PCR showed that human fetal pancre-
atic progenitor cells expressed stem cell markers (Oct4,
ABCG2, SCF and CD133), pancreatic ductal cells markers
(CAII and CK19) and pancreatic endocrine markers
(PDX-1 and Ngn 3) (Figure 2A). Two important stem
cell markers related to pancreatic development, PDX-1
and Ngn 3, were also verified by immunofluorescence
staining (Figure 2B).
To confirm the expansion of pancreatic progenitor
cells rather than mesenchymal cells, the cells from the
second, fifth and tenth passages were measured for ex-
pressions of SMA, vimentin and stem cells markers. The
results showed that stem cell markers Oct4, CAII and
PDX-1 did not fluctuate during expansion. SMA and
vimentin could be detected at passage two and the ex-
pression levels were maintained during expansion
(see Additional file 2) but insulin and glucagon were not
detectable in these cells.
Differentiation of pancreatic progenitor cells
To evaluate the differentiation of pancreatic progenitor
cells, several important stem cell markers and mature
endocrine cell markers were measured after differenti-
ation. The results of real-time PCR (Table 1) showed
that PDX-1 and neurogenin 3 were up-regulated during
differentiation. Insulin and glucagon expression became
detectable after a three-week induction period and were
significantly enhanced at Week 4, especially in islet-like
structures. GLUT1 was expressed in pancreatic stem
cells and increased during differentiation. VDCC, an-














Figure 3 Differentiation of pancreatic progenitor cells and
formation of islet-like structures. (A) The endocrine cells
differentiated from human fetal pancreatic progenitor cells, ×200. (B)
Islet-like structure formed by the differentiated cells, ×100. (C) Native
islet immunofluorescence stained for insulin (red) and glucagon
(green), DAPI used for nuclei staining (blue), ×400. (D) Progenitor
cell-derived islet immunofluorescence stained for insulin (red) and











Figure 2 Identification of human pancreatic progenitor cells.
(A) RT-PCR result for stem cell markers expressed on human fetal
pancreatic progenitor cells. A total of five fetal samples was studied, and
this image was from one sample from the 11th week of gestation. All
the experiments were repeated three times. (B) Immunofluorescence
staining for endocrine progenitor cell markers, PDX-1 and Ngn3, in
human fetal pancreatic progenitor cells.
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came further up-regulated at Week 4, especially in islet-
like structures. In addition, the exocrine markers of
HES-1 and amylase were also detectable, but their
expression levels did not fluctuate significantly before or
after differentiation (Table 1).Formation of islet-like structures in vitro
After four weeks of induction, the cells started exhibiting
fibroblast-like morphology (Figure 3A). Upon suspension
with extracellular matrix, islet-like structures formed
in the culture (Figure 3B). Unlike native human islets
with insulin-positive cells found in the center andTable 1 Quantitative analysis of various gene transcripts duri
GAPDH PDX-1 Ngn3 CAII Insulin G
0w cells 20.14 34.63 37.63 23.74 - - -
3w cells 20.78 33.80 36.80 18.87 31.23
4w cells 20.76 33.87 36.87 19.76 27.43
4w-islets 20.90 32.81 35.81 20.01 25.61
Data are means of △ cycle threshold values from cells of five different samples. W, wglucagon-positive cells at the periphery (Figure 3C),
these islet-like cell clusters had alpha and beta cells
scattered about (Figure 3D).
Insulin-releasing function of differentiated cells in vitro
To evaluate the insulin-releasing function of differentiated
cells, we first examined the insulin secretory granules by
transmission electron microscopy and immunfluorescence
staining. Both experiments confirmed the existence of
insulin secretory granules although much fewer than can
be seen in native islets (Figure 4A). Then, insulin secretion
of differentiated cells in response to glucose stimulation
was tested by ELISA. The results showed that the response
to 25 mM glucose stimulation seemed quite robust
(Figure 4B) with insulin gradually increasing over 24 hours
(Figure 4C).
Functions of differentiated cells in vivo
To examine their function in vivo, we transplanted the
differentiated islet-like structures under the left kidneyng differentiation
lucagon GLUT1 GLUT2 VDCC Hes1 Amylase
- - - 29.56 - - - - - - 33.83 31.55
29.40 28.80 33.87 33.86 33.46 31.41
26.20 27.89 31.84 31.17 33.81 31.10






































Figure 4 Evaluation of insulin secretory function of differentiated cells in vitro. (A) Detection of insulin secretory granules. Insulin granules
in the differentiated cells were detected by transmission electron microscopy (middle panel), with adult islet beta cells as positive control (left panel);
the insulin distribution in differentiated cells was granular by immunofluorescence staining (right panel). (B) Insulin release in differentiated cells and
islet-like structures upon glucose stimulation. (C) The time-effect relationship of insulin release in the response of differentiated cells to glucose. All the
experiments were repeated three times, and the results are presented as means ± SD.
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differentiated islets group decreased significantly com-
pared to the diabetic group two days after transplantation
(P <0.05) and stayed below 10 mM. There was no signifi-
cant difference in the blood glucose level between the
differentiated islets group and the control group two
days after transplantation. Hyperglycemia returned (over
20 mM) after left nephrectomy along with transplantedA B
Figure 5 Long-term evaluation of glycemia in diabetic animals after t
progenitor cells. (A) Glycemia in diabetic nude mice after transplantation
control group. N = 6 in each group. *P <0.05 (progenitor cells group versus
immunohistochemistry staining for human C-peptide and human mitochoislet-like structures (Figure 5A). Human C-peptide-
positive cells and human mitochondrion antigen-positive
cells were found under the capsule of the left kidney
(Figure 5B), which demonstrated the function and survival
of the graft.
This evidence suggests that the islet-like structures
derived from human fetal pancreatic progenitor cell can
survive and function in vivo.ransplantation with islets derived from human fetal pancreas
with progenitor cell differentiated islets. Normal mice comprise the
diabetes group). (B) Evaluation of the survival of grafted islets by
ndrion antigen.
Zhang et al. Stem Cell Research & Therapy 2013, 4:141 Page 7 of 8
http://stemcellres.com/content/4/6/141Discussion
Pancreatic β cell dysfunction and/or loss of pancreatic β cell
mass are key pathogenic factors for diabetes mellitus. Al-
though a preferred therapeutic strategy, islet transplantation
has been impeded by limited supply. Therefore, interest
in generating insulin-producing cells efficiently became
inevitable. Our study shows that human fetal pancreatic
progenitor cells can be expanded extensively and differenti-
ated into pancreatic endocrinal cells and islet-like structures
in vitro. After transplantation of such structures into
diabetic animals, euglycemia can be successfully restored
and maintained.
It has been reported that LIF, important for self-renewal,
can maintain stem cells in an undifferentiated stage [22]
and bFGF plays a crucial role in cell proliferation and
differentiation during embryonic development [12]. There-
fore, we expanded human fetal pancreatic progenitor cells
in vitro using culture medium containing LIF and bFGF.
Our study shows that human fetal pancreatic progenitor
cells exhibit a strong proliferation capability in this culture
medium. The number of these cells from one single
human fetal pancreas could be expanded to 1 × 1010.
During expansion, mesenchymal cell markers of SMA
and vimentin became positive at passage two and stayed
at the same level during the entire period. Due to the
high expression of stem cell marker in these cells,
EMT was suspected. Human pancreatic progenitors
were reported to transform into mesenchymal-like cells
through EMT in a growth-promoting medium. Upon re-
versal of EMT, these cells could form islet-like aggregates
of hormone-producing cells [17,23].
Similar to adult pancreatic stem cells, human fetal pan-
creatic progenitor cells expressed PDX-1 and neurogenin-3.
As a marker related to islet differentiation, PDX-1 was
expressed during differentiation into endocrine cells [15,24].
Other studies indicated that embryonic stem cells differ-
entiating into insulin-producing cells were also nestin
positive [5]. As a poly(ADP-ribose) synthetase inhibitor,
nicotinamide promotes cell differentiation and the expres-
sions of insulin and C peptide [25]. Thus, it has been
widely used in studies of stem cells differentiating into the
pancreatic endocrine lineage. Glucagon-like peptide-1,
all-trans retinoic acid and activin A also have been
demonstrated to be effective in inducing embryonic
stem cell transformation into insulin-producing cells [26].
After induction of human fetal pancreatic progenitor cells
with nicotinamide, glucagon-like peptide-1, all-trans retin-
oic acid and activin A, the expression of mature endocrine
cell markers, such as insulin, glucagon, GLUT2 and VDCC,
increased extensively and became further up-regulated in
islet-like structures.
It was found that islet-like structures formed when differ-
entiated endocrine cells were cultured in suspension with
medium containing extracellular matrix molecules, suchas laminin, collagen IV and fibronectin. The extracellular
matrix molecules mediated adherence between β cells
and contributed to proliferation and differentiation into
insulin-producing cell [27]. They could also enhance islets
survival, insulin expression and release in response to
glucose [28-30].
The insulin-releasing response to glucose (25 mM) was
found in differentiated cells and it was even stronger in
differentiated islet-like structures. Our previous study
showed that alpha-cell loss from islets impaired insulin
secretion in vitro and in vivo [31]. In the present study,
immunofluorescent staining revealed that islet-like struc-
tures contained both alpha and beta cells. However, the
distribution of alpha cells in the islet-like structures was
different from that in native islets.
It is known that insulin-producing cells derived from
human embryonic stem cells or human pancreatic islet
progenitor cells could correct hyperglycemia in diabetic
mice [32,33]. In the present study, differentiated islet-like
structures derived from human fetal pancreatic progenitor
cells could release insulin upon in vitro stimulation with
glucose and corrected hyperglycemia in diabetic animals
in vivo. Furthermore, histological examination revealed
that the grafted islet-like structures were of human origin
and immune-positive for human C-peptide.
Conclusions
With an excellent capacity for proliferation, human fetal
pancreatic progenitor cells may be induced to differentiate
into insulin-producing cells and form islet-like structures
in vitro. Capable of secreting insulin to reduce hypergly-
cemia after transplantation in diabetic animals, the resulting
islets might become a potential source for islets trans-
plantation in treatment for diabetes.
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